Trial Profile
An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 29 Jul 2019 Status changed from recruiting to completed.
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
- 14 Mar 2014 New trial record